Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (March 2024)

19 slides from Curis's investor presentation, March 2024

  1. Slide 1: Corporate Presentation

    Corporate Presentation March 2024

  2. Slide 2: Note regarding forward looking statements and disclaimers

    Note regarding forward looking statements and disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “w

  3. Slide 3: Curis is the leader of IRAK4 in oncology

    Snapshot Curis is the leader of IRAK4 in oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS; PoC study in PCNSL in combination with BTKi Thesis Sin

  4. Slide 4: Anti-cancer activity for emavusertib/ibrutinib combination in B-cell lymphoma updated at ASH 2023

    Lymphoma Anti-cancer activity for emavusertib/ibrutinib combination in B-cell lymphoma updated at ASH 2023 All patients, multiple types of B-cell lymphoma No Prior BTKi Failed Prior BTKi 0% MZL sCNS CLL MCL MCL WM WM MZL-N pCNS FL MZL-N pCNS pCNS pCNS pCNS -10% • Heavily pre-treated patients (1-10 p

  5. Slide 5: PCNSL selected as lead indication for POC in lymphoma

    Lymphoma PCNSL selected as lead indication for POC in lymphoma R/R PCNSL emavusertib in combination with ibrutinib 0% Rationale for selection of R/R PCNSL as lead POC study in lymphoma  Ultra-orphan indication small study size  MYD88-driven cancer good fit with emavusertib mechanism  Aggressive t

  6. Slide 6: Anti-cancer activity for emavusertib monotherapy in leukemia

    Leukemia Anti-cancer activity for emavusertib monotherapy in leukemia Next Step: Demonstrate Enrich for Optimize single-agent activity genetically-defined population for dose Continue enrollment to confirm these findings in a larger number of patients All patients, regardless of dose or mutation sta

  7. Slide 7: Emavusertib Molecular Design

    Emavusertib Molecular Design

  8. Slide 8: Emavusertib molecule specifically designed to hit multiple targets relevant in oncology

    Emavusertib Emavusertib molecule specifically designed to hit multiple targets relevant in oncology emavusertib was selected by NCI for its sponsored research Emavusertib Emavusertib and clinical studies of Kinase Interaction Map Binding Affinity IRAK4 FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRAK2 >20,

  9. Slide 9: Emavusertib in Leukemia

    Emavusertib in Leukemia a CUS’

  10. Slide 10: The two primary targets of emavusertib are independent drivers of cancer

    Leukemia The two primary targets of emavusertib are independent drivers of cancer IRAK4 FLT3 spliceosome mutations drive overexpression of IRAK4-L, which genetic mutations cause constitutive activation of FLT3 and constitutively activates the myddosome, driving NF-ĸB overactivity downstream cell gro

  11. Slide 11: Rationale for monotherapy vs. combination

    Leukemia Rationale for monotherapy vs. combination Targeted Population Targeted Population All Comers Monotherapy in IRAK4 Monotherapy in FLT3 Combination with Aza/Ven 100% “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incur

  12. Slide 12: Anti-cancer activity for emavusertib monotherapy in R/R AML

    Leukemia Anti-cancer activity for emavusertib monotherapy in R/R AML Reduction in Marrow Blast (for target populations dosed at 300 mg BID RP2D) Targeted Patients with Targeted Patients with • Safety profile established in dose escalation study of 0% FLT3 mutation* Spliceosome mutation* 0% emavusert

  13. Slide 13: Emavusertib is a novel molecule demonstrating single-agent and combination anti-cancer activity

    Leukemia Emavusertib is a novel molecule demonstrating single-agent and combination anti-cancer activity • IRAK4 is a novel and important target in AML 1  Primary driver of disease in > 50% of AML patients  Secondary or tertiary driver in nearly all patients Leukemia Study Next Step: Continue enro

  14. Slide 14: Emavusertib in Lymphoma

    Emavusertib in Lymphoma a CUS’

  15. Slide 15: Combination therapy provides complementary inhibition of two pathways driving NF-κB

    Lymphoma Combination therapy provides complementary inhibition of two pathways driving NF-κB Two Pathways Drive Lymphoma Clinical Strategy: Block Both Pathways BCR and TLR Pathways independently drive NF-κB overactivity Blocking both the TLR (with IRAK4) and BCR (with BTK) Pathways (and NF-κB overac

  16. Slide 16: PCNSL selected as lead indication for POC in lymphoma

    Lymphoma PCNSL selected as lead indication for POC in lymphoma R/R PCNSL emavusertib in combination with ibrutinib 0% Rationale for selection of PCNSL as lead POC study in lymphoma  Ultra-orphan indication small study size  MYD88-driven cancer good fit with emavusertib mechanism  Aggressive tumor

  17. Slide 17: Emavusertib is a novel molecule demonstrating single-agent and combination anti-cancer activity

    Lymphoma Emavusertib is a novel molecule demonstrating single-agent and combination anti-cancer activity • Patients are currently treated with BTKi because it downregulates NF-κB Lymphoma Study • Two pathways drive NF-κB: Next Step: Continue enrolling in 1) BCR Pathway: addressed by blocking BTK • C

  18. Slide 18: Curis is the leader of IRAK4 in oncology

    Snapshot Curis is the leader of IRAK4 in oncology Investment Emavusertib is a novel, highly-active IRAK4 inhibitor with potential cornerstone utility in heme and solid tumors Full development program underway in front-line and end-stage AML/MDS; PoC study in PCNSL in combination with BTKi Thesis Sin

  19. Slide 19: End of Corporate Presentation

    End of Corporate Presentation

Curis — Investor Presentation (March 2024) on 6ix